JP2018526450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526450A5 JP2018526450A5 JP2018531280A JP2018531280A JP2018526450A5 JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5 JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- promoter
- composition according
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215651P | 2015-09-08 | 2015-09-08 | |
| US62/215,651 | 2015-09-08 | ||
| PCT/KR2016/009866 WO2017043815A1 (en) | 2015-09-08 | 2016-09-02 | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526450A JP2018526450A (ja) | 2018-09-13 |
| JP2018526450A5 true JP2018526450A5 (https=) | 2019-08-29 |
| JP6895968B2 JP6895968B2 (ja) | 2021-06-30 |
Family
ID=58240110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531280A Expired - Fee Related JP6895968B2 (ja) | 2015-09-08 | 2016-09-02 | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10646524B2 (https=) |
| EP (1) | EP3347460A4 (https=) |
| JP (1) | JP6895968B2 (https=) |
| KR (1) | KR102674362B1 (https=) |
| CN (1) | CN108350434B (https=) |
| AU (1) | AU2016320355B2 (https=) |
| CA (1) | CA2996120C (https=) |
| HK (1) | HK1255192A1 (https=) |
| WO (1) | WO2017043815A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| JP6827467B2 (ja) * | 2015-06-19 | 2021-02-10 | シルラジェン，インコーポレイテッド | ウイルス塞栓術のための組成物および方法 |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| WO2019148109A1 (en) | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| MX2021003013A (es) * | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2022524951A (ja) | 2019-02-27 | 2022-05-11 | アクティム・セラピューティクス・インコーポレイテッド | 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌 |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| IL300447A (en) | 2020-08-12 | 2023-04-01 | Actym Therapeutics Inc | Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA |
| US20240102912A1 (en) * | 2020-11-09 | 2024-03-28 | Thrive Bioscience, Inc. | Plaque counting assay method |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE01918975T1 (de) * | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Mikrokügelchen zur aktiven Embolisierung |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| AU2012204467B2 (en) * | 2011-01-04 | 2016-08-18 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
-
2016
- 2016-09-02 WO PCT/KR2016/009866 patent/WO2017043815A1/en not_active Ceased
- 2016-09-02 EP EP16844635.9A patent/EP3347460A4/en not_active Withdrawn
- 2016-09-02 US US15/758,689 patent/US10646524B2/en active Active
- 2016-09-02 JP JP2018531280A patent/JP6895968B2/ja not_active Expired - Fee Related
- 2016-09-02 HK HK18114315.9A patent/HK1255192A1/zh unknown
- 2016-09-02 KR KR1020187009770A patent/KR102674362B1/ko active Active
- 2016-09-02 CN CN201680064990.2A patent/CN108350434B/zh active Active
- 2016-09-02 CA CA2996120A patent/CA2996120C/en active Active
- 2016-09-02 AU AU2016320355A patent/AU2016320355B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526450A5 (https=) | ||
| Park et al. | Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer | |
| Khosravi et al. | Immunologic tumor microenvironment modulators for turning cold tumors hot | |
| Buqué et al. | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer | |
| Vilgelm et al. | Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy | |
| Takeda et al. | A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy | |
| JP6949131B2 (ja) | 治療用ｒｎａ | |
| Fridlender et al. | Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms | |
| Cui et al. | Generation of effector CD8+ T cells and their conversion to memory T cells | |
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| Di Carlo et al. | Depletion of slow-cycling PDGFRα+ ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis | |
| CN114729358A (zh) | 涉及miRNA-193a的新疗法 | |
| JP2022524391A (ja) | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| CN108841796A (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| Perales-Puchalt et al. | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment | |
| Du et al. | Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer | |
| JP2019532047A (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| Sutanto et al. | Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity | |
| Guo et al. | In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence | |
| He et al. | Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy | |
| Verner et al. | Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy | |
| Shi et al. | Ultrasound‑targeted microbubble destruction‑mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function | |
| Sun et al. | Recombinant oncolytic vaccinia viruses expressing human β-defensin 2 enhance anti-tumor immunity | |
| Shi et al. | A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses |